Defining and treating high-risk multiple myeloma

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Multiple myeloma (MM) is increasingly understood as a heterogeneous plasma cell disorder.
• Patient outcomes in MM vary significantly due to clinical and biological factors.
• Risk stratification categorizes MM patients into standard, intermediate, and high-risk groups.

Purpose of the Study:

• To review current therapeutic approaches for patients with high-risk multiple myeloma.
• To consolidate information on predictors of poor outcomes in MM.

Main Methods:

• Literature review of available data on high-risk MM.
• Analysis of patient-specific, clinical, and biological features associated with adverse outcomes.
• Synthesis of evidence regarding optimal treatment strategies.

Main Results:

• High-risk MM is characterized by specific patient factors (e.g., older age, poor performance status), clinical features (e.g., primary plasma cell leukemia, extramedullary disease), and biological markers (e.g., del(17p), t(4;14), high-risk gene expression profiles).
• These factors predict increased risk of disease relapse, morbidity, and mortality.

Conclusions:

• Effective management of high-risk multiple myeloma requires tailored therapeutic strategies.
• Further research is needed to optimize treatment protocols for this challenging patient subgroup.